Variant allele frequency as a predictor of treatment response to osimertinib in EGFR‑mutated NSCLC
Variant allele frequency was evaluated as a potential predictive factor for overall survival (OS).
Variant allele frequency (VAF) is evaluated as a potential predictive factor for overall survival (OS) in patients with EGFR‑mutated non‑small cell lung cancer (NSCLC) treated with first‑line osimertinib. Data from 147 multi‑center NSCLC patients showed a mean OS of 31.4 months for VAF ≥30% versus 19.7 months for VAF <30%, and a mean progression‑free survival (PFS) of 25.0 months versus 18.2 months, respectively.
Assessing VAF may identify patients who are more likely to benefit from first‑line osimertinib, enabling more personalized treatment decisions for EGFR‑mutated NSCLC.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT